Regulation of Stem Cell Therapy Travel
- 63 Downloads
Purpose of Review
Stem cell therapies (hereinafter: SCT) hold tremendous promise for the treatment of a variety of diseases. Yet, alongside the medical potential, they pose significant risks. This article focuses on the phenomenon of “SCT travel” and the regulatory challenges associated with it.
Internet websites for clinics all around the world offer SCT for different medical conditions, such as degenerative and immunological conditions, as well as cosmetic indications. The demand for SCT is growing, despite their experimental nature, and an effective regulatory framework is urgently needed at both national and international levels.
A new regulatory framework aimed at reducing the risks associated with SCT travel and the provision of unproven SCT should be implemented. It should include professional guidelines, an accreditation system that would evaluate SCT being offered by clinics, enforcement mechanisms against fraud, reimbursement by insurers for approved SCT, and residency requirements.
KeywordsDirect-to-consumer Hype Internet Regulation Stem cell therapy Stem cell tourism
We would like to thank Leigh Turner and Amy Zarzeczny for providing helpful feedback on this manuscript.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
- 9.Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029. https://doi.org/10.1371/journal.pmed.1000029.
- 10.DeRenzo L. Stem cell tourism: the challenge and promise of international regulation of embryonic stem cell-based therapies. Case W Res J Int’l L. 2011;43(3):877–918.Google Scholar
- 18.•• O’Donnell L, Turner L, Levine AD. The role of communication in better understanding unproven cellular therapies. Cytotherapy. 2016;18(1):143–8. https://doi.org/10.1016/j.jcyt.2015.11.002. This article touches on the commercial use of SCT and the different strategies companies use to convince patients of the benefits of such therapies. CrossRefPubMedGoogle Scholar
- 20.• von Tigerstrom B. Regulating the advertising and promotion of stem cell therapies. Regen Med. 2017;12(7):815–26. https://doi.org/10.2217/rme-2017-0057. This article discusses the potential and limits of using consumer protection laws and advertising laws in order to prevent the provision of unproved SCT. CrossRefGoogle Scholar
- 21.Lee TL, Lysaght T, Lipworth W, Hendl T, Kerridge I, Munsie M, et al. Regulating the stem cell industry: needs and responsibilities. Bull World Health Organ. 2017;95(9):663–4. https://doi.org/10.2471/BLT.16.189977.
- 23.The Food and Drug Administration (FDA). Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and Regen Med 2017 Aug 28. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573443.htm.
- 24.• Knoepfler P. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev. 2015;82-83:192–6. https://doi.org/10.1016/j.addr.2014.12.001. This article addresses core issues and emerging trends regarding the regulatory oversight of SCT in the USA. CrossRefPubMedGoogle Scholar
- 26.Deasy BM, Anderson JE, Zelina S. Regulatory issues in the therapeutic use of stem cells. In: Anderson JE, editor. Regenerative medicine and tissue engineering. Rijeka: InTech; 2013.Google Scholar
- 27.The Food and Drug Administration (FDA). Regulatory considerations for human cell, tissues, and cellular and tissue-based products: minimal manipulation and homologous use: guidance for industry and Food and Drug Administration staff. 2017 Nov. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf.
- 28.The Food and Drug Administration (FDA). FDA announces comprehensive regenerative medicine policy framework: framework aims to spur innovation, efficient access to potentially transformative products, while ensuring safety and efficacy. 2017 Nov 16. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585345.htm.
- 29.The Food and Drug Administration (FDA). Same surgical procedure exception under 21 CFR 1271.15(b): questions and answers regarding the scope of the exception: guidance for industry. 2017 Nov. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM419926.pdf.
- 31.Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance).Google Scholar
- 32.Regulation (EC) no 726/2004 of the European Parliament and of the council of 31 march 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European medicines agency (Text with EEA relevance).Google Scholar
- 34.United States v Regenerative Sciences, 741 F3d 1314 (2014).Google Scholar
- 35.The Food and Drug Administration (FDA). FDA warns US stem cell clinic of significant deviations. 2017 Aug 28. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573431.htm.
- 36.The Food and Drug Administration (FDA). FDA acts to remove unproven, potentially harmful treatment used in “stem cell” centers targeting vulnerable patients. 2017 Aug 28. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573427.htm.
- 42.•• Tigerstrom BV. Revising the regulation of stem cell-based therapies: critical assessment of potential models. Food Drug Law J. 2015;70(2):315–37. This article examines recent attempts to craft a more flexible regulatory framework of SCT. Google Scholar
- 43.Tretyakov K, Cohen G. Medical assistance in dying and “suicide tourism” to Canada: bill C-14 from a comparative perspective. JEMH. 2016;Google Scholar
- 44.Pettitt D, Brindley D. The commercialization of cell and gene therapies: regulatory challenges. RegMedNet 2017 May 2. Available from: https://www.regmednet.com/users/3641-regmednet/posts/16428-the-commercialization-of-cell-and-gene-therapies-regulatory-challenges.
- 45.The International Society for Stem Cell Research (ISSCR). Guidelines for stem cell research and clinical translation 2016 Available from: http://www.isscr.org/docs/default-source/all-isscr-guidelines/guidelines-2016/isscr-guidelines-for-stem-cell-research-and-clinical-translation.pdf?sfvrsn=4.
- 46.Servick K. Under 21st century cures legislation, stem cell advocates expect regulatory shortcuts. Science 2016 Dec 12. Available from: http://www.sciencemag.org/news/2016/12/under-21st-century-cures-legislation-stem-cell-advocates-expect-regulatory-shortcuts-0.
- 47.Right to Try Act, 2014 Ariz Legis Serv H Con Res 2005 (codified at ARIZ REV STAT ANN §§ 36–1311 to −1314 (West Supp 2015)); Right to Try Act, 2014 Colo Legis Serv Ch 220 (HB 14–1281) (codified at COLO REV STAT §§ 25–45-101 to −108 (2015)).Google Scholar
- 48.Servick K. Texas has sanctioned unapproved stem cell therapies. Will it change anything?. Science 2017 June 15. Available from: http://www.sciencemag.org/news/2017/06/texas-has-sanctioned-unapproved-stem-cell-therapies-will-it-change-anything.
- 50.EuroStemCell. Patient access to unproven stem cell treatments: a human rights issue?. Available from: https://www.eurostemcell.org/considering-stem-cell-treatment-offer.
- 51.EuroStemCell. Scientists raise alarm as Italian Government rules on unproven stem cell therapy. Available from: https://www.eurostemcell.org/scientists-raise-alarm-italian-government-rules-unproven-stem-cell-therapy.
- 52.•• Matthews KRW, Iltis AS. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders. BMC Med Ethics. 2015;16(75):1–11. https://doi.org/10.1186/s12910-015-0069-x. This article elaborates on the negative consequences of unproven SCT and advocates for a more appropriate model for addressing SCT tourism. CrossRefGoogle Scholar
- 53.• Gharaibeh B, Anderson JE, Deasy BM. Combating the threat of stem cell tourism through patient education and government regulation. Innov Entrep Health. 2016;2016(3):15–24. https://doi.org/10.2147/IEH.S56239. This article focuses on patients’ needs for educational resources on SCT. CrossRefGoogle Scholar
- 55.Zarzeczny A, Caulfield T, Ogbogu U, Bell P, Crooks VA, Kamenova K, et al. Professional regulation: a potentially valuable tool in responding to “stem cell tourism”. Stem Cell Reports. 2014;3(3):379–84. https://doi.org/10.1016/j.stemcr.2014.06.016.
- 57.• Ogbogu U. Combating unlicensed stem cell interventions through truthful advertising law: a survey of regulatory trends. McGill JL Health. 2015–2016;9(2):311–35. This article advocates for the use of truthful advertising laws and enforcement strategies in order to combat the provision of unproven SCT. Google Scholar